TGFB2 and non-small cell lung carcinoma: An allogeneic tumor cell, gene-modified vaccine called Lu-canixTM (NovaRx, San Diego, CA, USA) is tested for four distinct NSCLC cancer cell lines that suppress TGF-β2 expression and boost immunogenicity by producing a TGF-β2 antisense gene [175,176].